drugset / Trial / NCT03848481

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

NCT03848481 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to examine the feasibility and safety of cannabidivarin (CBDV) as a treatment for children and young adults with PWS.

Timeline

Start
2020-11-23
Primary completion
2024-10-31
Completion
2024-10-31

Outcome

Outcome not reported

Stopped (Business): “Only limited funding was available and the study was never able to be conducted to its natural conclusion.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidivarin Small molecule 10 mg/kg —

Indications